**Trends in HRT use**

|  |  |  |
| --- | --- | --- |
| *Country*  *Population*  *Age-range* | *HRT use* | *References* |
| Australia  Population-based survey (n=907)  40 years and older | Peaked in 2001 at 21% and Decreased to 12% by 2002  Returned to 19% by 2003 | ([Main and Robinson, 2008](#_ENREF_16), [MacLennan et al., 2004](#_ENREF_15), [Zbuk and Anand, 2012](#_ENREF_33)) |
| Canada  National Population Health Survey (n=1,200)  50-69 | Peaked at 30-45% in 2002  Decreased to 15% by 2004 and 13.7% in 2006 | ([Zbuk and Anand, 2012](#_ENREF_33), [De et al., 2010](#_ENREF_7), [Neutel and Morrison, 2010](#_ENREF_20)) |
| China  Shanghai Women’s Health Study cohort (n=74,942)  “after menopause” | Estimated 3% in 1997-2000 | ([Linos et al., 2008](#_ENREF_13)) |
| Denmark  Danish Medicines Agency  Age range? | Peaked at 11% in 2003  Decreased to 9.7% in 2004 and to 9% in 2005 | ([von Euler-Chelpin, 2011](#_ENREF_32)) |
| Finland  Nationwide register study  45 years and older | Peaked at 21% in 2003  Decreased to 12% in 2012 | ([Holm et al., 2014](#_ENREF_9)) |
| France  National reimbursement data  50-64 years | Peaked in 2001 at 32% Decreased to 11% by 2007 | ([Zbuk and Anand, 2012](#_ENREF_33), [Seradour et al., 2009](#_ENREF_26)) |
| Iceland  Survey (n=561)  47-53 years | 22% in 2004  (Ref Icelandic study 57% of 52-57 year olds 1996-2001) | ([Sveinsdóttir and Olafsson, 2006](#_ENREF_29)) |
| Israel  HMO population (n=251,000)  45 years and older | 20% in 2001  10% in 2007 | ([Silverman and Kokia, 2009](#_ENREF_27)) |
| Italy  Milan prescriptions file  50-69 years | Estimated at 12% in 2003  6.9% in 1999-2001 | ([Manzoli et al., 2004](#_ENREF_17), [Crocetti et al., 2010](#_ENREF_6)) |
| Japan  Community survey (n=8791)  45-64 years | 2.5% in 1992 | ([Nagata et al., 1996](#_ENREF_19)) |
| Korea  Marketing data  50 years and older | Decreased by 39% from 2002 to 2006, then ‘increased slightly’ to 2009.  4.5% in 2010 | ([Cho and Park, 2011](#_ENREF_5), [Kim et al., 2010](#_ENREF_10)) |
| Luxembourg |  | Nil |
| Netherlands  EPIC Cohort (n=17,357)  49-70 years | Peaked at 13% 1993 - 1997  Decreased to 11.4% in 2002-2003 and to 6.6% by 2005 | ([Soerjomataram et al., 2007](#_ENREF_28), [van Duijnhoven et al., 2006](#_ENREF_30)) |
| New Zealand  Population-based survey (n=318)  45-64 years | 20% in 1997  Decreased to 11% in 2002 | ([Bilgrami et al., 2004](#_ENREF_2), [North and Sharples, 2001](#_ENREF_21)) |
| Norway  Official Drug Statistics and Oslo Health Study (57% of Oslo women)  59-60 years | 46% of 59-60 year olds in 2000-2001 (Oslo)  Decreased in Norway by 67% from 1999 to 2007 | ([Meyer et al., 2009](#_ENREF_18), [Zbuk and Anand, 2012](#_ENREF_33)) |
| Poland  Representative national sample (n=1,544)  45-64 years | 12% in 2002 (before WHI Trial results) | ([Rachon et al., 2004](#_ENREF_24)) |
| Portugal  Cohort (n=382)  “Postmenopausal” | Lifetime prevalence of HRT use unchanged from 1985-2005 | ([Lucas and Barros, 2008](#_ENREF_14)) |
| Saudi Arabia  Tertiary care hospital chart review (n=144)  56-59 years | 46% in 2000 (before WHI Trial results) | ([Kirkby and Saif, 2004](#_ENREF_11)) |
| Spain  Primary healthcare centre population (n=371)  45-65 years | 11% in 1998  8.6% in 2002 | ([Pollán et al., 2010](#_ENREF_23), [Zbuk and Anand, 2012](#_ENREF_33), [Bermejo and Perez, 2005](#_ENREF_1)) |
| Sweden  National pharmacy data  50-59 years | Peaked at 36% in 1999  Declined to 27% in 2002 and 9% in 2007 | ([Lambe et al., 2010](#_ENREF_12)) |
| Switzerland  Swiss Drug Register  45-49 years | 35-50% in 1996  46% in 2002 | ([Verkooijen et al., 2008](#_ENREF_31), [Bouchardy et al., 2006](#_ENREF_3), [Schaad et al., 2000](#_ENREF_25)) |
| United Kingdom  Million Women Study  45-69 years | 27.7% in 1998  25% in 2000-2001  12% in 2006 | ([Bromley et al., 2004](#_ENREF_4), [Parkin, 2009](#_ENREF_22)) |
| United States  National prescription and therapeutic index databases  50-74 years | Peaked at 42% in 2001  Declined to 28% in 2003 | ([Hersh et al., 2004](#_ENREF_8)) |
| Uruguay |  | No published information |

|  |  |
| --- | --- |
|  |  |

**References**

BERMEJO, M. J. & PEREZ, I. R. 2005. Physicians and the prescription of hormone replacement therapy in Spain. *Health Policy,* 73**,** 58-65.

BILGRAMI, I., BLOWER, K., FENG, J., STEFANKO, G. & TAN, E. 2004. Changes in the use of hormone replacement therapy in New Zealand following the publication of the Women’s Health Initiative trial. *Journal of the New Zealand Medical Association,* 117.

BOUCHARDY, C., MORABIA, A., VERKOOIJEN, H. M., FIORETTA, G., WESPI, Y. & SCHÄFER, P. 2006. Remarkable change in age-specific breast cancer incidence in the Swiss canton of Geneva and its possible relation with the use of hormone replacement therapy. *BMC cancer,* 6**,** 78.

BROMLEY, S. E., DE VRIES, C. S. & FARMER, R. D. 2004. Utilisation of hormone replacement therapy in the United Kingdom. A descriptive study using the general practice research database. *BJOG,* 111**,** 369-76.

CHO, M. K. & PARK, H. M. 2011. The national use of hormonal therapy in postmenopausal women in 2010. *The Journal of Korean Society of Menopause,* 17**,** 150-154.

CROCETTI, E., BUZZONI, C., FALCINI, F., CORTESI, L., DE LISI, V., FERRETTI, S., TUMINO, R., RUSSO, A. & PACI, E. 2010. Disentangling the roles of mammographic screening and HRT in recent breast cancer incidence trends in Italy by analyses based on calendar time and time since screening activation. *The breast journal,* 16**,** 350-355.

DE, P., NEUTEL, C. I., OLIVOTTO, I. & MORRISON, H. 2010. Breast cancer incidence and hormone replacement therapy in Canada. *Journal of the National Cancer Institute,* 102**,** 1489-1495.

HERSH, A. L., STEFANICK, M. L. & STAFFORD, R. S. 2004. National use of postmenopausal hormone therapy: annual trends and response to recent evidence. *JAMA,* 291**,** 47-53.

HOLM, E., AALTONEN, K., HEIKKINEN, A.-M. & TIIHONEN, M. 2014. From systemic hormone therapy to vaginal estrogen–a nationwide register study in Finland, 2003–2012. *Maturitas*.

KIM, J. Y., SANG, J. H. & PARK, H. M. 2010. The change of hormone therapy in postmenopausal women in Korea before and after women's health initiative study: 2000~ 2009. *Korean Journal of Obstetrics and Gynecology,* 53**,** 1110-1117.

KIRKBY, R. & SAIF, A. 2004. Screening, supplements and the use of hormonal replacement therapy in postmenopausal women in a family medicine department prior to the publication of the Woman's Health Initiative report. *Annals of Saudi medicine,* 24**,** 175-178.

LAMBE, M., WIGERTZ, A., HOLMQVIST, M., ADOLFSSON, J., BARDAGE, C., FORNANDER, T., KARLSSON, P., ODLIND, V., PERSSON, I. & AHLGREN, J. 2010. Reductions in use of hormone replacement therapy: effects on Swedish breast cancer incidence trends only seen after several years. *Breast cancer research and treatment,* 121**,** 679-683.

LINOS, E., SPANOS, D., ROSNER, B. A., LINOS, K., HESKETH, T., QU, J. D., GAO, Y.-T., ZHENG, W. & COLDITZ, G. A. 2008. Effects of reproductive and demographic changes on breast cancer incidence in China: a modeling analysis. *Journal of the National Cancer Institute,* 100**,** 1352-1360.

LUCAS, R. & BARROS, H. 2008. Life prevalence of hormone replacement therapy and profile of users have not changed among women with self-reported menopause in the last two decades in Porto, Portugal. *Climacteric,* 11**,** 26-31.

MACLENNAN, A. H., TAYLOR, A. W. & WILSON, D. 2004. Hormone therapy use after the women's health initiative. *Climacteric,* 7**,** 138-142.

MAIN, P. & ROBINSON, M. 2008. Changes in utilisation of hormone replacement therapy in Australia following publication of the findings of the Women's Health Initiative. *Pharmacoepidemiology and drug safety,* 17**,** 861-868.

MANZOLI, L., DI GIOVANNI, P., DEL DUCA, L., DE ALOYSIO, D., FESTI, D., CAPODICASA, S., MONASTRA, G., ROMANO, F. & STANISCIA, T. 2004. Use of hormone replacement therapy in Italian women aged 50-70 years. *Maturitas,* 49**,** 241-51.

MEYER, H. E., LOFTHUS, C. M., SOGAARD, A. J. & FALCH, J. A. 2009. Change in the use of hormone replacement therapy and the incidence of fracture in Oslo. *Osteoporos Int,* 20**,** 827-30.

NAGATA, C., MATSUSHITA, Y. & SHIMIZU, H. 1996. Prevalence of hormone replacement therapy and user's characteristics: a community survey in Japan. *Maturitas,* 25**,** 201-207.

NEUTEL, C. I. & MORRISON, H. 2010. Could recent decreases in breast cancer incidence really be due to lower HRT use? Trends in attributable risk for modifiable breast cancer risk factors in Canadian women. *Can J Public Health,* 101**,** 405-9.

NORTH, F. & SHARPLES, K. 2001. Changes in the use of hormone replacement therapy in New Zealand from 1991-1997. *The New Zealand medical journal,* 114**,** 250-253.

PARKIN, D. M. 2009. Is the recent fall in incidence of post-menopausal breast cancer in UK related to changes in use of hormone replacement therapy? *European Journal of Cancer,* 45**,** 1649-53.

POLLÁN, M., MICHELENA, M., ARDANAZ, E., IZQUIERDO, A., SÁNCHEZ-PÉREZ, M. & TORRELLA, A. 2010. Breast cancer incidence in Spain before, during and after the implementation of screening programmes. *Annals of oncology: official journal of the European Society for Medical Oncology/ESMO,* 21**,** iii97-102.

RACHON, D., ZDROJEWSKI, T., SUCHECKA-RACHON, K., SZPAKOWSKI, P., BANDOSZ, P., MANIKOWSKI, A. & WYRZYKOWSKI, B. 2004. Knowledge and use of hormone replacement therapy among Polish women: estimates from a nationally representative study--HORTPOL 2002. *Maturitas,* 47**,** 31-7.

SCHAAD, M.-A., BONJOUR, J.-P. & RIZZOLI, R. 2000. Evaluation of hormone replacement therapy use by the sales figures. *Maturitas,* 34**,** 185-191.

SERADOUR, B., ALLEMAND, H., WEILL, A. & RICORDEAU, P. 2009. Changes by age in breast cancer incidence, mammography screening and hormone therapy use in France from 2000 to 2006. *Bull Cancer,* 96**,** E1-6.

SILVERMAN, B. G. & KOKIA, E. S. 2009. Use of hormone replacement therapy, 1998-2007: sustained impact of the Women's Health Initiative findings. *Annals of Pharmacotherapy,* 43**,** 251-8.

SOERJOMATARAM, I., COEBERGH, J. W., LOUWMAN, M. W., VISSER, O. & VAN LEEUWEN, F. E. 2007. Does the decrease in hormone replacement therapy also affect breast cancer risk in the Netherlands? *Journal of Clinical Oncology,* 25**,** 5038-5039.

SVEINSDÓTTIR, H. & OLAFSSON, R. F. 2006. Women's attitudes to hormone replacement therapy in the aftermath of the Women's Health Initiative study. *Journal of advanced nursing,* 54**,** 572-584.

VAN DUIJNHOVEN, F. J., VAN GILS, C. H., BEZEMER, I. D., PEETERS, P. H., VAN DER SCHOUW, Y. T. & GROBBEE, D. E. 2006. Use of hormones in the menopausal transition period in the Netherlands between 1993 and 1997. *Maturitas,* 53**,** 462-475.

VERKOOIJEN, H. M., KOOT, V., FIORETTA, G., VAN DER HEIDEN, M., SCHIPPER, M., RAPITI, E., PEETERS, P., PETERSE, J. & BOUCHARDY, C. 2008. Hormone replacement therapy, mammography screening and changing age-specific incidence rates of breast cancer: an ecological study comparing two European populations. *Breast cancer research and treatment,* 107**,** 389-395.

VON EULER-CHELPIN, M. 2011. Breast cancer incidence and use of hormone therapy in Denmark 1978–2007. *Cancer Causes & Control,* 22**,** 181-187.

ZBUK, K. & ANAND, S. S. 2012. Declining incidence of breast cancer after decreased use of hormone-replacement therapy: magnitude and time lags in different countries. *Journal of epidemiology and community health,* 66**,** 1-7.